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Background and Objectives: This current study assessed the value of S‐100B
measurement to guide fluorodeoxyglucose (FDG) positron emission tomography/
computed tomography (PET/CT) scanning for detecting recurrent disease in stage III
melanoma patients.
Methods: This study included 100 stage III melanoma patients in follow‐up after
curative lymph node dissection. Follow‐up visits included physical examination and
S‐100B monitoring. FDG PET/CT scanning was indicated by clinical symptoms and/or
elevated S‐100B.
Results: Of 100 patients, 13 (13%) had elevated S‐100B without clinical symptoms, of
whom 7 (54%) showed disease evidence upon FDG PET/CT scanning. Twenty‐six
patients (26%) had clinical symptoms with normal S‐100B and FDG PET/CT revealed
metastasis in 20 (77%). Three patients had clinical symptoms and elevated S‐100B,
and FDG PET/CT revealed metastasis in all three (100%). Overall, FDG PET/CT
scanning revealed metastasis in 30 of the 42 patients (71.4%). For seven recurrences,
elevated S‐100B prompted early detection of asymptomatic disease; 10% of all
asymptomatic patients in follow‐up, 23% of all patients with recurrent disease.
Conclusion: S‐100B cannot exclude recurrent disease during follow‐up of stage III
melanoma. However, adding S‐100B measurement to standard clinical assessment
can guide FDG PET/CT scanning for detecting recurrent melanoma.
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1 | INTRODUCTION
The incidence of cutaneous melanoma has increased worldwide over
recent decades.1 In the Netherlands, 1563 new cases were diagnosed in
1990, and this number grew to 6743 in 2017.2 Mortality has increased
at a lower rate, with 348 melanoma‐related deaths in 1990 in the
Netherlands, and 767 in 2016. The lower rise in mortality is because the
increased incidence largely involves more cases of thin melanoma, likely
due to improved awareness and earlier melanoma detection.1,3
In melanoma patients, the goal of follow‐up surveillance is the
cost‐effective detection of recurrence at an early stage, based on
the assumption that early surgical and/or systemic treatment will
improve disease‐free survival (DFS), melanoma‐specific survival
(MSS), and overall survival (OS). There are no clinical data to support
this assumption. Until now, data on the effectiveness of routine
imaging for recurrence detection in follow‐up is limited. Data with
respect to an impact on the quality of life in melanoma patients
with intensive follow‐up schedules are lacking.4
The melanoma biomarker S‐100B reportedly shows strong
correlations with distant metastasis‐free survival and OS in stage
IIB‐III melanoma patients.5 The serum concentration of S‐100B is
correlated with disease stage, and S‐100B is an independent predictor
of melanoma prognosis in patients undergoing therapeutic lymph node
dissection (TLND) for nodal macro‐metastases.6,7 German melanoma
follow‐up guidelines added the melanoma biomarker S‐100B and
Italian guidelines added both S‐100B and fluorodeoxyglucose (FDG)
positron emission tomography/computed tomography (PET/CT) scan-
ning, in addition to regular patient history and physical examination.8,9
Specifically, S‐100B measurement has been recommended for use in
some follow‐up guidelines in the selection of stage III patients to
undergo FDG PET/CT scanning. However, the added value of this
screening is unknown.10,11 Assessment of the melanoma marker could
potentially contribute to the detection of asymptomatic disease
recurrence in stage III melanoma, and therewith reduce the number
of routine FDG PET/CT scans. As long as scientific data on the effect
of standard scanning regimens are lacking, a strategy using a
biomarker as a trigger for scanning in asymptomatic patients could
be an interesting alternative.
In the present study, we primarily aimed to assess the added
value of the biomarker S‐100B as a selection tool before FDG PET/
CT scanning for the detection of recurrent disease in stage III
melanoma patients. Our secondary objective was to evaluate the
associated costs of this follow‐up strategy.
2 | MATERIALS AND METHODS
2.1 | Patients
This investigation included all patients with stage III melanoma who
underwent curative treatment with complete lymph node dissection
(CLND) for a positive sentinel node, or with TLND for macro‐
metastases, and were treated at the Division of Surgical Oncology of
the University Medical Center Groningen (UMCG), the Netherlands.
The study protocol was applied to all stage III melanoma patients
who were in follow‐up in 2015, and to all newly diagnosed patients
since 2015. Study data were collected during the period 2015‐2018.
Patients who underwent off‐protocol FDG PET/CT imaging during
this time period were excluded from the present analysis. Data
collection was conducted according to the declaration of Helsinki
ethical principles for medical research involving human subjects.12
2.2 | Follow‐up
Outpatient follow‐up visits included patient medical history, physical
examination, and serum S‐100B and LDH laboratory testing following
the UMCG protocol (Table 1).
Serum S‐100B level laboratory calculations were performed as
previously described.7 The S‐100B cut‐off value was ≥0.15 µg/L. S‐100B
level was defined as borderline if it was between 0.10 and 0.15 µg/L
and/or showed a ≥40% elevation compared to the last measurement. A
change of ≥40% was considered statistically significant based on the
biological and analytical variations of S‐100B.13
FDG PET/CT scanning was performed in cases with clinical
suspicion of recurrent melanoma and/or an elevated S‐100B level.
In cases with borderline S‐100B values, measurement was repeated
after 4 weeks, and FDG PET/CT scanning was performed when
S‐100B was persistently borderline or elevated (Figure 1). The
indication for FDG PET/CT scanning was recorded, and categorized
into three groups: (a) clinical symptoms and normal S‐100B, (b)
clinical symptoms and elevated S‐100B, and (c) no clinical symptoms
and elevated S‐100B.
2.3 | Costs
For all patients participating in the UMCG follow‐up protocol, we
calculated the follow‐up costs of the detection of asymptomatic and
symptomatic recurrences, including S‐100B measurement, as well as
the total costs of FDG PET/CT scanning. Data were acquired from
the Patient Financial Department of the UMCG.
3 | RESULTS
3.1 | Patients
A total of 122 patients with stage III melanoma were in follow‐up
during the study period. The median follow‐up after CLND or TLND
was 4.7 years (0.7‐15.3 years). We excluded 22 patients due to
TABLE 1 Follow‐up protocol for stage III melanoma at UMCG
Years of follow‐up Outpatient visit + S‐100B measurement
1st year 4× per year
2nd year 3× per year
3rd‐5th year 2× per year
>5th year 1× per year
Abbreviation: UMCG, University Medical Center Groningen.
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off‐protocol FDG PET/CT scanning. Of the remaining 100 patients,
52 were male and 48 were female, and the median age was 57 years
(range, 25‐89 years) (Table 2). During the study period, the 100
patients attended a total of 456 outpatient visits with corresponding
S‐100B measurements (Table 3).
3.2 | Indications for PET/CT
During the 456 outpatient visits, elevated S‐100B was found
42 times (9.2%) (Table 3). Of the 100 patients, 58 patients (58%)
F IGURE 1 Clinical follow‐up and S‐100B measurement, 3‐month interval




Female, n, % 48 (48.0%)
Male, n, % 52 (52.0%)
Years of age, median (range) 57 (25‐89)
Primary melanoma site, n, %
Head 4 (4%)
Trunk/back 36 (36%)
Lower extremity 41 (41%)
Upper extremity 15 (15%)
Unknown primary 4 (4%)













Type of melanoma, n, %
Superficial spreading 64 (64%)
Nodular melanoma 21 (21%)
Verrucous nevoid melanoma 1 (1%)
Spitzoid melanoma 1 (1%)
Other 13 (13%)
Abbreviations: CLND, completion lymph node dissection; TLND,
therapeutic lymph node dissection.
TABLE 3 Overview of follow‐up visits, S‐100B tests, and FDG
PET/CT scans
Patient assessment
Years of follow‐up, median (range) 4.7 (0.7‐15.3)
S‐100B samples, N 456
Normal, n, % 414 (90.8%)
Elevated,a n, % 42 (9.2%)
Indication for FDG PET/CT scan, n, %
Symptoms 26 (62%)
Symptoms + elevated S‐100B 3 (7.1%)
Elevated S‐100B 10 (23.8%)
S‐100B level elevation ≥40% 3 (7.1%)
Total FDG PET/CT scans,b N 42
Positive FDG PET/CT scans, n (%) 30 (71.4%)
Negative FDG PET/CT scans, n (%) 12 (28.6%)
Abbreviations: FDG, fluorodeoxyglucose; PET/CT, positron emission
tomography/computed tomography.
aAll elevated S‐100B samples, including repeated measurements from a
single patient in cases showing an S‐100B elevation of ≥40%.
bOne FDG PET/CT scan per patient; additional scans performed after one
positive FDG PET/CT scan were not counted.
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had no clinical suspicion of recurrence or elevated S‐100B level
during their follow‐up visits, and thus had no indication for FDG
PET/CT scanning. The remaining 42 patients (42%) had clinical
symptoms and/or elevated S‐100B and, therefore an indication for
FDG PET/CT scanning. Thirteen patients were asymptomatic but
had elevated S‐100B levels (in 54% recurrent melanoma on PET/
CT). Twenty‐six patients presented with clinical symptoms and a
normal S‐100B level (in 77% recurrence on PET/CT). Three patients
had both clinical symptoms and elevated S‐100B (100% recurrence
on PET/CT) (Table 4).
Of all 100 patients, 26 had symptoms without S‐100B
elevation, which leaves 74 asymptomatic patients in this cohort.
Thirteen of these asymptomatic patients (18%) had elevated
S‐100B levels and seven (10%) showed recurrent disease on the
FDG PET/CT scan.
3.3 | Yield per PET/CT indication
A total of 42 FDG PET/CT scans were obtained in this study, of which
30 (71%) showed evidence of recurrent disease. Of these
30 disease‐revealing FDG PET/CT scans, 7 (23%) were performed
based on elevated S‐100B levels in asymptomatic patients. The
remaining 23 disease‐revealing scans were performed based on clinical
symptoms (77%), 3 with and 20 without elevated S‐100B measure-
ments. Twelve FDG PET/CT scans were negative, 6/29 symptomatic
patients (21%) (with and without elevated S‐100B) and 6/13 patients
with elevated S‐100B (46%) (P = .09) (Table 4, Figure 2).
3.4 | Stage and recurrence pattern
Of the 30 disease‐revealing FDG PET/CT scans, 15 patients were
initially diagnosed with (AJCC version 8) stage IIIA disease, 8 with stage
IIIB, 5 with stage IIIC and 2 with stage IIID. The 12 negative FDG PET/
CT scans included 2 stage IIIA, 7 stage IIIB and 3 stage IIIC patients.
Differences in recurrence pattern were found for the 20
symptomatic and the 7 asymptomatic patients. Of the 20 sympto-
matic patients, 12 (60%) presented with locoregional recurrences,
5 (25%) with distant recurrences, and 3 (15%) with both locoregional
and distant recurrences. For asymptomatic patients scanned for high
S‐100B, five of seven patients (71.4%) had distant and two patients
(28.6%) locoregional metastases.
3.5 | Costs
The total S‐100B laboratory costs and the costs of FDG PET/CT
scanning for all 100 stage III melanoma patients undergoing follow‐
up under the UMCG protocol were calculated. In 2015, the cost of
processing a single S‐100B sample was €109 and the cost of a FDG
PET/CT scan was €913. The total cost was €88.050 for all S‐100B
samples (456 in total) processed during follow‐up of 100 patients
plus the cost of the 42 FDG PET/CT scans.
When a standard scan protocol (eg, as suggested in the TRIM [A
Randomized Trial to Assess the Role of Imaging During Follow up After
Radical Surgery of High Risk Melanoma] study [NCT03116412]) is
applied to the same cohort with corresponding follow‐up and costs as in
the current study, total diagnostic costs (FDG PET/CT and S‐100B)
would have been €408.800 (100 patients in follow‐up with S‐100B and
FDG PET/CT at baseline, 86 patients at 6 months, 78 patients at
12 months, 69 patients at 24 months and 67 patients at 36 months).
4 | DISCUSSION
The present study evaluated the tumor marker S‐100B in stage III
melanoma patients as an additional tool to guide FDG PET/CT scanning
for the detection of recurrent disease. Of all S‐100B measurements,
2.9% eventually led to FDG PET/CT scanning. However, S‐100B was the
only trigger for the FDG PET/CT scan in 23% of all patients in whom
recurrent disease was detected. For all asymptomatic patients in follow‐
up, S‐100B measurement led to the discovery of recurrent disease in
10% of them. Clearly, S‐100B measurement cannot exclude disease
during follow‐up of stage III melanoma. However, our findings show that
the tumor marker can serve as an extra tool, in addition to standard
TABLE 4 Indications for FDG PET/CT scanning and their association with recurrent disease
Positive FDG PET/CT scan (n = 30) Negative FDG PET/CT scan (n = 12)
Indication for FDG PET/CT scan Symptomatic vs asymptomatic Symptomatic vs asymptomatic
Symptoms (n = 26) 20 (76.9%) 23 (77%) 6 (23.1%) 6 (50%)
Symptoms + S‐100B (n = 3) 3 (100%) 0 (0%)
Elevated S‐100B (n = 13) 7 (53.8%) 7 (23%) 6 (46.2%) 6 (50%)
Abbreviations: FDG, fluorodeoxyglucose; PET/CT, positron emission tomography/computed tomography.
F IGURE 2 PET outcome proportionally classified for indication
for 42 of 100 scanned patients. PET, positron emission tomography
[Color figure can be viewed at wileyonlinelibrary.com]
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clinical assessment, to guide FDG PET/CT scanning for the detection of
recurrent disease, without the financial, logistical, and radiation burdens
of a standard scanning follow‐up scheme.
In cases of cutaneous melanoma, S‐100B serum concentrations
are a prognostic marker of metastatic disease.5,7 Serum concentra-
tions of S‐100B correlate with disease stage, although large variation
is observed with or without S‐100B elevation.6 Previous findings
suggest that S‐100B levels may be influenced by the melanoma
metastasis location and by variations in the ability of melanoma cells
to produce S‐100B.14-16 Together with the limited S‐100B elevation
in patients with low tumor load, it is difficult to designate S‐100B as a
solid indicator of recurrence.17
In the current study, disease recurrence was detected on
FDG PET/CT scans that were performed in 7 patients (23%) with
elevated S‐100B and no clinical symptoms, in 3 patients (10%) with
clinical symptoms and elevated S‐100B, and in 20 patients (67%)
with clinical symptoms and normal S‐100B. These data correspond
with previous findings that elevated S‐100B was the only sign in
20% of patients with disease progression.16 In the present series,
33% of patients that recurred IV disease had increased S‐100B,
which is in line with prior reports of increased S‐100B levels in 4%
to 100% of patients with stage IV disease.6 In stage II and III
melanoma patients, the reported sensitivity and specificity of S‐
100B for recurrent disease varies from 29% to 43% and 93% to
94%, respectively.7,11,18
To compare with other tumor markers, the widely accepted
colorectal cancer biomarker carcino‐embryonic antigen (CEA) has a
41% to 97% sensitivity, which is somewhat higher, and a 52% to
100% specificity, which is comparable to that of S‐100B.19 A recent
study revealed that 1.5% of all CEA measurements from curatively
treated patients with stage I‐III colorectal cancer ultimately led to
recurrence detection.20,21 As with S‐100B, a normal CEA level does
not exclude recurrent disease.22
Tumor markers can be used in cancer detection and diagnosis,
but are mainly used in follow‐up to detect recurrent disease in an
early phase.23 The recent development of successful systemic
treatment options for stage IV melanoma have given rise to a
greater need for early detection of recurrence. It remains unclear
whether earlier diagnosis and treatment of stage IV disease with
immune or targeted therapy further contributes to improved MSS
and OS rates, as lead‐time bias may occur.24,25 Recent literature
suggests a routine substage‐III‐specific FDG PET/CT schedule for
asymptomatic detection of recurrences. However, the same lead‐
time bias argument as for biomarkers might be applicable.26 A
randomized trial is required to determine whether the gained time
reflects real survival time or just earlier knowledge of disease. At
the present time, it is clear that adjuvant therapy has advantages
over therapies in metastatic settings, and that more durable
responses and improved long‐term survival are observed with low
tumor load.27-30
The Swedish Melanoma Study Group has initiated a trial
investigating the effectiveness of standard imaging in Sweden (TRIM
study; NCT03116412). This prospective randomized multicenter
study of the roles of imaging and laboratory testing during follow‐up
after radical surgery of stage IIB‐III melanoma was proposed in 2017,
with OS as the study endpoint. Based on the scheduled outpatient
visits, with corresponding FDG PET/CT scans (€913) and S‐100B
samples (€109), the follow‐up costs for 100 patients using the TRIM
protocol would be €408.800 compared to the cost of €88.050 in our
current study. Compared to the UMCG protocol applied in our
present study, the standard scanning proposed in the TRIM study
might lead to earlier detection of metastases, but would also
greatly increase melanoma follow‐up costs and the radiation burden.
Moreover, the additional scans would lead to incidental findings not
contributing to melanoma treatment or disease‐related survival.31
The current study protocol could reduce FDG PET/CT scans in
asymptomatic melanoma patients, thereby reducing their radiation
exposure and the total follow‐up costs compared to a standard
scanning protocol. However, one must be aware that normal S‐100B
levels do not exclude metastatic disease, emphasizing the importance
of thorough self‐inspection by patients and physical examination
during follow‐up visits.
There are guidelines, based on AJCC version 8, that advice stage
IIIC and IIID often receive routine scans, sometimes even stage
IIIB.11,32 Most patients, who have undergone a FDG PET/CT scan in
this study were stage IIIA or IIIB. This means using S‐100B in
selecting for FDG PET/CT scan results in a more refined follow‐up
system.
This study has limitations. First, most patients were included
retrospectively and on‐protocol follow‐up was 3 years as the
median follow‐up since stage III diagnosis was 4.7 years. This
makes the population more heterogeneous and might influence the
recurrence risk. It could be one reason for the slightly lower
number of recurrences (30%) than the 38% reported in a recent
published study that used routine, substage‐specific stage III PET/
CT scanning schedule.26 Secondly, the present study cannot
determine the exact survival gain associated with earlier stage
IV diagnosis, or the effect of lead‐time bias. In addition, it is
difficult to define what the exact gained S‐100B detection
percentage is. When the detection rate is calculated over all
followed asymptomatic stage III patients the percentage would be
10% (7/71). However, a biomarker can never detect recurrent
disease in those patients that in fact do not have a recurrence.
When the gain is calculated for the patients that during this study
proved recurr (n = 30), this number is 23% (7/30), which could be
an overestimation because there might still have been patients is
the study follow‐up with occult recurrent disease.
Therefore, we conclude that the addition of S‐100B measure-
ment in the follow‐up of stage III melanoma prompted detection of
stage IV disease in 10% of all asymptomatic stage III patients, and
resulted in 23% additional upstaging. Without the use of S‐100B
there would have been no indication for FDG PET/CT scanning in
this 10% of asymptomatic patients, and 23% of all recurrences
would have been found later. In an era with expanding possibilities
for systemic melanoma treatment and where routine scanning is a
contested practice, there is growing demand for earlier stage IV
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diagnosis. Adding S‐100B measurement to follow‐up could be a
way to support this demand, when patients are still asymptomatic.
Future research is needed to optimize its use, to assess the
absolute survival gain, and compare to the efficacy and costs of
this follow‐up method with those of standard scanning protocols.
Research should also focus in the future on patient and tumor
characteristics that may predict the sensitivity of S‐100B during
follow‐up, with the aim of identifying patient subgroups in which S‐
100B shows higher sensitivity, to maximize the effectiveness of
this tool.
5 | CONCLUSIONS
S‐100B cannot exclude recurrent disease during follow‐up of stage III
melanoma. However, adding S‐100B measurement to standard
clinical assessment can effectively guide FDG PET/CT scanning for
detecting recurrent melanoma. Future studies are needed to
determine whether this protocol is a good alternative to follow‐up
regimens that include standard scheduled FDG PET/CT scans.
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